ReviewFrontiers in immunology2026
Targeting cGAS-STING-macrophage axis: a novel therapeutic horizon for renal fibrosis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Mechanism and Application of Traditional Chinese Medicine Nano-Formulations in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal fibrosis, a pivotal pathological hallmark of chronic kidney disease (CKD), arises from persistent inflammatory responses and extracellular matrix (ECM) deposition. Emerging evidence indicates the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling pathway has exerted a crucial influence on the progression of renal fibrosis. This pathway exacerbates the release of inflammatory factors and ECM deposition through reprograming the polarization state of macrophages, thereby driving renal fibrosis. This review delineates the regulatory role of the cGAS-STING signaling pathway in macrophage-related renal fibrosis and critically evaluates emerging innovative strategies targeting this pathway, including small molecule inhibitors, nanocarrier-based delivery systems, and gene editing technologies. However, current research still faces certain limitations, including the complexity of molecular mechanisms, differences in research results, and challenges in clinical translation. By synthesizing recent advances in cGAS-STING-mediated macrophage reprogramming for renal fibrosis intervention, this review aims to provide a foundation for precise therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.